CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced its financial results Wednesday for the three and 12 months ended June 30.

Over the quarter of fiscal 2021, the Austin, -based company closed an initial public offering of its $3.08 million shares of common stoke at $7 million, for gross proceeds of $21.5 million. On May 7, the company's stock debuted on the Nasdaq Capital Market under the symbol ANEB.

In addition, the management plans to use the proceeds for the company's planned business operations and clinical studies through the end of the calendar year 2022, as it's on schedule to launch Phase 2 proof-of-concept …

Full story available on Benzinga.com

More CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials